Feeds
Abbott Laboratories said Thursday it is buying a potential chronic pain drug from PanGenetics BV for as much as $190 million.
Abbott Laboratories said Wednesday it beat its own expectations for the third quarter as sales of its drug Humira continued to climb, along with sales of medical products and nutritional formula for children.
Drug and medical-device company Abbott Laboratories is scheduled to reports earnings for the third quarter on Wednesday. The following is a summary of key developments and analyst opinion related to the period.
Solvay, the Belgian chemical and pharmaceutical group, said Monday it has agreed to sell its entire pharmaceutical business to Abbott Laboratories of Abbott Park, Illinois, for euro5.2 billion ($7.6 billion).
Abbott Laboratories on Monday said it would pay $6.6 billion for the pharmaceutical business of Belgian chemicals maker Solvay in a move to further expand internationally and add to its product portfolio.
Stocks began the fourth quarter with their worst drop in three months after reports on the job market and manufacturing reawakened investors' pessimism about the economy. The slide intensified in the final minutes of the day, signaling that traders were growing nervous ahead of the government's key September jobs report due before the opening bell Friday. Bond prices jumped as investors sought a safer place for their money.
Abbott Laboratories says results of a large study place its artery-opening Xience stent on equal footing with competitor Boston Scientific in diabetics, a difficult-to-treat group of patients.
The Food and Drug Administration has approved a new test from Abbott Laboratories that detects both types of the virus that causes AIDS.
Abbott Laboratories on Wednesday said it will acquire Visiogen Inc. for $400 million in cash, in a move to expand its vision care segment.
Medical device maker Medtronic Inc. reported a 38 percent drop in fiscal first-quarter earnings Tuesday due to restructuring charges and legal fees from a patent dispute. Without the charges, the company's results narrowly beat Wall Street expectations.
Abbott Laboratories says it's expanding a study of its top-selling heart stent, Xience (ZEYE-ehnce) V, by more than 2,000 patients.
Abbott Laboratories Inc. is expanding a study of its top-selling heart stent by more than 2,000 patients, who may also be put in a second, landmark stent study meant to find the best way to prevent potentially fatal blood clots.
Abbott Laboratories said Tuesday it is expanding its nutritional business footprint in India with the $130 million buyout of a Wockhardt Ltd. unit.
Medtronic Inc. said Monday it agreed to pay Abbott Laboratories $400 million to settle patent lawsuits related to the design of artery-opening stents, some of the most lucrative medical devices marketed by either company.
Drug developer and medical device maker Abbott Laboratories said Wednesday its second-quarter profit fell 3 percent on a mix of buyout charges and lower drug sales, but the results still met Wall Street forecasts.
A federal appeals court has rejected a lawsuit accusing Abbott Laboratories of antitrust violations over a sudden 400-percent price hike of a popular AIDS drug.
Abbott Laboratories plans to appeal a jury's $1.67 billion patent infringement ruling in a case involving two blockbuster drugs that treat rheumatoid arthritis and other immune disorders.
A unit of Johnson & Johnson said Monday that a federal jury has ordered Abbott Laboratories to pay $1.67 billion in a patent infringement suit over the companies' rheumatoid arthritis drugs.
Abbott Laboratories and AstraZeneca PLC on Thursday asked the Food and Drug Administration to approve a drug that combines their cholesterol pills TriLipix and Crestor.
Abbott Laboratories reported a first-quarter profit that edged past Wall Street expectations, though analysts focused on weaker sales growth for its blockbuster drug Humira, sending shares lower Wednesday.
Abbott Laboratories Inc. Chairman and Chief Executive Miles White saw a 13.9 percent reduction in his total compensation in 2008 to $25.3 million, mainly because he received less in stock options, in a year in which profit and sales rose.
Sales of Abbott Laboratories' blockbuster drug Humira combined with double-digit growth of medical devices and nutritionals to push profit up 28 percent in the fourth quarter, even as its competitor Johnson & Johnson showed signs of vulnerability.
Medical products and drug maker Abbott Laboratories said Monday it is buying Advanced Medical Optics Inc. for about $1.36 billion plus debt to expand its eye-care offerings, including laser vision correction.
Abbott Laboratories Inc. said Wednesday its third-quarter profit jumped 51 percent, led by sales of the arthritis medication Humira and a steep increase in sales of stents and other heart-related devices.
Drug and medical device maker Abbott Laboratories said Thursday it will cut 1,000 jobs as part of a multiyear effort to lower spending on its medical testing business.
Log In | Register
